Virax Biolabs Group Limited is restructuring its senior management to streamline operations and reduce costs while prioritizing ViraxImmune development. The company eliminated the standalone Chief Operating Officer position, making Dr. Nigel McCracken's role redundant. He enters paid garden leave on October 5, 2026, with employment terminating December 23, 2026; he will remain a board director and receive statutory redundancy plus payment in lieu of notice. The Board appointed Clement Monteil as Acting Chief Scientific Officer for six months effective immediately. Dr. Monteil has served as Head of R&D since 2022. Virax Biolabs Group Limited operates in the biotechnology sector, focusing on vaccine development and manufacturing.
